Compare Consumer Staples Select Sector SPDR Fund (XLP) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consumer Staples Select Sector SPDR Fund vs Zimmer Biomet Holdings Inc — how do they compare? Consumer Staples Select Sector SPDR Fund trades at $83.4 (market cap $13.50B), while Zimmer Biomet Holdings Inc trades at $88.96 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consumer Staples Select Sector SPDR Fund for 72 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| XLP | ZBH | |
|---|---|---|
Market Cap | $13.50B | $16.95B |
Volume | 14,599,953 | 2,505,240 |
52-Week High | $90.00 | $103.98 |
52-Week Low | $75.61 | $79.58 |
Typical Hold Time | 72 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.41, up 2.09% with bullish technical signals from moving averages and oscillators. The ETF shows strong relative performance, gaining 6.6% year-to-date while consumer discretionary stocks declined. Analyst sentiment is unanimously positive with 100% buy ratings, supported by the fund's low 0.08% expense ratio and defensive positioning during market volatility.
The outlook remains favorable given XLP's defensive characteristics amid economic uncertainty, though rising interest rates pose a headwind. The ETF's focus on household staples provides stability, with dividend income adding to total return potential. Key risks include inflation pressures and consumer spending shifts toward value-oriented options.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
